Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Richmond, W.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

When and how to measure lipids and their role in CHD risk prediction

William Richmond

Chemical Pathology, St Mary's Hospital, Praed Street, Paddington, London, W2 1NY, UK, w.richmond{at}imperial.ac.uk

Accurate lipid and lipoprotein measurements, control of pre-analytical factors and consideration of biological variability are required for the reliable assessment of coronary heart disease (CHD) risk and the management of dyslipidaemia. Inclusion of high density lipoprotein-cholesterol, in addition to total cholesterol, in risk calculations is preferred to attain good sensitivity and specificity. Although the strong and independent association of triglyceride with CHD has been confirmed, its large biological variation limits its utility as a risk factor or primary treatment target. A fasting profile including triglyceride is essential however for consideration of genetic and secondary causes of dyslipidaemia and decisions on therapeutic intervention.

Key Words: lipids • lipoproteins • CHD risk • biological variation.

References

  • Kannel WB, Wilson PWF. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992;124:768-74.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gotto AM High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002;144:S33-S42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Castelli WP The triglyceride issue: a view from Framingham. Am Heart J 1986;112:432-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Manninen V., Tenkanen L., Koskinen P. et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992;85:37-45.[Abstract/Free Full Text]
  • Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Durrington PN Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis 1998;141:S57-S62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Abbot RD, Carroll RJ Interpreting multiple logistic regression coefficients in prospective observation studies. Am J Epidemiol 1984;119:830-60.[Abstract/Free Full Text]
  • Phillips AN, Davey Smith G. How independent and `independent effects'? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991;44:86-91.
  • Packard C., Caslake M., Shepherd J. The role of small, dense, low density lipoprotein (LDL): A new look. Int J Cardiol 2000;74:517-22.
  • Sniderman AD, Cianflone K. Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias. Clin Chem 1996;42:489-91.[Free Full Text]
  • Griffin BA, Freeman DJ, Tait G. et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions. Relative contribution of small dense LDL to coronary heart disease risk. Atherosclerosis 1994;106:241-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stampfer MJ, Sacks FM, Salvini S., Willett WC, Hennekens CH The Physicians Health Study. N Engl J Med 1991;325:373-81.[Abstract]
  • Grover SA, Coupal L., Xiao-Ping H. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995;274:801-06.[Abstract/Free Full Text]
  • The International Task Force for Prevention of Coronary Heart Disease /International Atherosclerosis Society. Coronary heart disease: reducing the risk. Nutr Metab Cardiovasc Dis 1998;8:205-71.[Web of Science]
  • Executive Summary of the Third Report of the National Cholesterol EducationProgram (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.[Free Full Text]
  • Wood D., De Backer G., Faegman O. et al., together with members of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998;140:199-270.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on detection, evaluation and treatment of high blood cholesterol in adults. Heart 1998;80(suppl 2):S1-S29.[Free Full Text]
  • Jackson R. Updated New Zealand Cardiovascular disease risk-benefit prediction guide. BMJ 200;320:709-10.[CrossRef]
  • Wilson S., Johnston A., Poulter NR et al. Predicting coronary risk in the general population - is it necessary to measure high-density lipoprotein cholesterol? J Cardiovasc Risk 2003;10:137-41.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Durrington PN, Prais H., Bhatnagar D. et al. Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet 1999; 353:278-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Game FL, Jones AF Coronary heart disease risk assessment in diabetes mellitus - a comparison of PROCAM and Framingham risk assessment functions. Diabet Med 2000;8:355-9.
  • Jones AF, Walker J., Game FL et al. Comparative accuracy of cardiovascular risk prediction methods in primary care patients. Heart 2001;85:37-43.[Abstract/Free Full Text]
  • Durrington PN, Prais H. Methods for the prediction of coronary heart disease. Heart 2001;85:489-90.[Free Full Text]
  • Durrington PN Rigorous detection and vigorous treatment of familial hypercholesterolaemia. Lancet 2001;357:574-5.[Medline] [Order article via Infotrieve]
  • National Service Framework for coronary heart disease. London: Department of Health, 2000 (www.doh.gov.uk/nsf/coronary.htm#chdnsf).
  • McNamarra JR, Teng Leary E., Ceriotti F. et al. Point Status of lipid and lipoprotein standardisation. Clin Chem 1997;43:1306-14.[Abstract/Free Full Text]
  • Myers GL, Kimberly MM, Waymack PP et al. A reference method laboratory network for cholesterol: a model for standardisation and improvement of clinical laboratory measurements. Clin Chem 200;46:1762-72.
  • Ricos C., Alvarez F., Cava JV et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999;59:491-500.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fraser CG, Harris EK Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.[Web of Science][Medline] [Order article via Infotrieve]
  • Jessen HJ, Dass CJ, Eckfeldt JH Do enzymatic analyses of serum triglycerides really need blanking for free glycerol. Clin Chem 1990;3:1372-5.
  • Nauck M., Warnick R., Rifai N. Methods for measurement of LDL cholesterol: A critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002;48:236-54.[Abstract/Free Full Text]
  • Scharnagi H., Nauck M., Wieland H., Marz W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001;39:426-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Miremadi S., Sniderman A., Frohlich J. Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders? Clin Chem 2002;48:484-8.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 3, 191-198 (2003)
DOI: 10.1177/14746514030030030601
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Richmond, W.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?